Table 1.

Immunotherapy (αPD1 and αCTLA4) response probability based on logistic regression models of tumor mutational burden (TMB), neoepitope burden (Neoepitopes), and combined tumor DNA- and RNA- variant burden (TVB) for melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). P values are reported on a per-model basis without correction for multiple comparisons per cancer type

Cancer type & Metric	aPD1			aCTLA4			p-value
	N	Response Probability (25th %ile)	Response Probability (75th %ile)	N	Response Probability (25th %ile)	Response Probability (75th %ile)
Melanoma
TMB	50	0.456	0.507	195	0.298	0.342	0.267
Neoepitopes	50	0.470	0.507	195	0.302	0.334	0.378
TVB	27	0.367	0.490	61	0.307	0.424	0.079
NSCLC
TMB	33	0.291	0.578				0.034
Neoepitopes	33	0.345	0.583				0.053
RCC
TMB	50	0.656	0.666				0.894
Neoepitopes	50	0.662	0.66				0.973
TVB	17	0.641	0.538				0.600